Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany

SURE Germany studied the use of once-weekly (OW) subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in adults with type 2 diabetes (T2D) in real-world practice. It was a multicentre, prospective, non-interventional study enrolling adults with T2D (duration≥12 weeks) and documented HbA1c ≤ 12 weeks before initiating OW semaglutide at their physician's discretion.

Baseline characteristics ( n=779) were: mean age, 60.2 years ; male, 56.1%; diabetes duration, 11.4 years; HbA1c, 8.0%; body weight (BW), 107.5 kg; waist circumference (WC), 121.0 cm; and body mass index (BMI), 36.4 kg/m2. At baseline: 97.4% received anti-hyperglycaemic medications (oral anti-hyperglycaemic drugs [OADs], 36.2%; GLP-1RAs, 19.0%; insulin±OADs without GLP-1RA, 42.2%); 56.4%, 37.1% and 21.1% had HbA1c < 8.0%, < 7.5% and < 7.0%, respectively.

On study completion (~30 weeks; n=669) mean semaglutide dose was 0.76 mg . Patients experienced significant reductions in mean (95% confidence interval) HbA1c (primary endpoint; –1.0%-point [–1.06;–0.93]) , BW ( –4.5 kg [–4.88;–4.04]) and WC (–4.8 cm [–5.37;-4.18]); all p<0.0001. At the final timepoint, HbA1c < 8.0%, < 7.5% and < 7.0% was achieved by 550 (84.2%), 465 (71.2%) and 353 (54.1%) patients, respectively; 351 (53.3%) and 251 (38.1%) achieved BW reductions ≥ 3% and ≥ 5%, respectively. Five different serious adverse drug reactions were reported for three patients (0.4%). A total of 39 documented hypoglycaemic episodes were reported, none were severe.

In routine clinical practice in Germany, patients with T2D treated with OW semaglutide experienced clinically significant improvements in HbA1c, BW and WC, supporting real-world use.

10. Grundlagenforschung Typ-1-Diabetes/Betazelle | Grundlagenforschung Typ 2-Diabetes | Grundlagenforschung Adipositas/Fettgewebe (I)

Publication History

Article published online:
26 May 2022